Bruce Cooper, MD, Vice President and Head of Global

Medical Affairs at AstraZeneca, said, "Diabetes is a growing epidemic worldwide, which is associated with significant comorbidities that contribute to an increased risk of costly hospitalisation and even death.

"Real-world data from this study provides striking evidence that the newer SGLT-2i class of medicines cuts the rate of hospitalisation for heart failure and death by approximately half."

The hospitalisation for heart failure analysis was conducted using anonymised patient data from Denmark, Germany, Norway, Sweden, United Kingdom and the United States.

Of the data reviewed, 41.8 per cent of patients were on Farxiga (dapagliflozin), 52.7 per cent on canagliflozin and 5.5 per cent on empagliflozin.

The analysis of death from any cause was conducted using anonymised patient data from the same countries.

(This article has not been edited by DNA's editorial team and is auto-generated from an agency feed.)